Focus: Remix Therapeutics is a public biotech company founded in 2020 that develops small molecule therapies designed to reprogram RNA processing, with a focus on gene therapy applications. The company is in early clinical stage with a lean pipeline focused on oncology and hematology indications.
Profile data last refreshed 16h ago · AI intelligence enriched 2d ago
Stable — net +3 jobs in 30d
3 added, 0 removed. Backfill posture.
Remix is a high-risk, high-novelty early-stage play best suited for scientists and clinicians seeking platform exposure and startup equity upside, not stability or rapid advancement.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Remix Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Remix Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Remix Therapeutics Selected for Late-Breaking Oral Presentation at the 38th EORTC-NCI-AACR Symposium - The Manila Times
Remix Therapeutics Selected for Late-Breaking Oral Presentation at the 38th EORTC-NCI-AACR Symposium The Manila Times
Remix Therapeutics™ Appoints Michael Landsittel to Board of Directors - The Manila Times
Remix Therapeutics™ Appoints Michael Landsittel to Board of Directors The Manila Times
Remix Therapeutics™ Appoints Michael Landsittel to Board of Directors - Yahoo Finance
Remix Therapeutics™ Appoints Michael Landsittel to Board of Directors Yahoo Finance
Remix Therapeutics Appoints Nicole Sweeny as Chief Commercial Officer - The Manila Times
Remix Therapeutics Appoints Nicole Sweeny as Chief Commercial Officer The Manila Times
Remix Therapeutics Appoints Nicole Sweeny as Chief Commercial Officer - citybiz
Remix Therapeutics Appoints Nicole Sweeny as Chief Commercial Officer citybiz
8-K Filing: Passage BIO, Inc. (PASG) (CIK 0001787297) — 8-K
8-K
Showing 6 of 10 news items
Based on last 4 crawl cycles
Recent peer-reviewed publications with author affiliations at this company
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo